Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Marketing Trumps Science in Vytorin Scandal
- In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...
- Blog posts 2008-04-01
- FDA Approves New Indication for ZETIA® - Merck/Schering-Plough's Cholesterol Lowering Drug - For Administration in Combination with Fenofibrate, along With Diet
- WHITEHOUSE STATION & KENILWORTH, N.J. -- Expanded Indication for ZETIA Offers a New Treatment Alternative for Patients with Mixed Hyperlipidemia
- Research articles 2006-06-09
- Schering-Plough, Merck score big. (Life Sciences).(receives FDA approval for cholesterol drug, Zetia)
- THE $19 BILLION cholesterol market has been jolted by Food and Drug Administration FDA approval of Zetia ezetimibe, the first new class of drug behind a 15-year reign by statins. The development is good news for Schering-Plough Corp. SHP and THE $19 BILLION...
- Research articles 2002-11-04
- Cholesterol boost for AstraZeneca.
- AstraZeneca's drug Crestor has produced the biggest reduction in bad cholesterol ever seen in a trial of 'statin' drugs, when used in combination with Merck's cholesterol absorption inhibitor Zetia. Data presented at a conference this week showed tha AstraZeneca's drug Crestor has produced the biggest reduction...
- Research articles 2006-06-23
- Enhancing employee health
- What's for lunch today? Pizza and potato chips? Fish and salad? We love choices at mealtime, but many of us make poor ones by eating too many fatty foods. That's why millions of Americans have high cholesterol, a major risk factor for heart disease and st What's for lunch today?...
- Research articles 2006-06-01
- Merck's Troubled Cholesterol Drug Vytorin Awaits Rescue -- Three Years Too Late
- In the silent movie era, a damsel would often be tied to the railroad tracks by a villain only to be rescued in the nick of time by the hero. At Merck MRK, a tortured version of that scenario is emerging on the beleagured Vytorin cholesterol franchise, except that...
- Blog posts 2010-03-12
- Marketing Trumps Science in Vytorin Scandal
- In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...
- Blog posts 2008-04-01
Additional Resources
- Niaspan trounces Zetia, spurring debate
- Well, analysts were right about that much-anticipated cholesterol drug study. Abbott Laboratories' Niaspan pill did indeed beat out Merck's Zetia at unclogging arteries, according to study results presented at the American Heart Association meeting yesterday. Cardiologists expect the data to boost niacin use--and serve as a further drag on sales...
- News items 2009-11-16
- Vytorin gaining market share without sapping Zetia
- SINCE LAUNCHING last year, Schering-Plough's dual-action cholesterol-lowering product Vytorin has risen to sixth among the top nine lipid-lowering drugs, without cannibalizing sales of the firm's blockbuster cholesterol pill, Zetia. Vytorin is a combination of Zetia ezetimibe and Merck's Zocor simvastatin. Simvastatin reduces production of LDL, or "bad cholesterol," in the...
- Research articles 2005-10-01
- Leerink Outlines Gloom Potential for Merck/Schering's $2B Zetia Franchise
- Analysts at Leerink Swann have unearthed more somewhat speculative evidence that the result of Merck and Schering-Plough's "Arbiter 6" comparison of their Zetia cholesterol drug versus Abbott Labs' Niaspan went badly for Zetia. by Jim Edwards
- Blog posts 2009-08-17
- Vytorin and Zetia fail in heart study
- CHICAGO -- Leading doctors urged a return to older, tried-and- true treatments for high cholesterol after hearing full results Sunday of a failed trial of Vytorin and related drug Zetia. Millions of Americans already take the drug or one of its components, Zetia. But doctors were stunned to...
- Research articles 2008-03-31
- Data about Zetia risks was not fully revealed by Merck and Schering-Plough, evidence suggests
- Merck and Schering-Plough have conducted several studies of their popular cholesterol medicine Zetia that raise questions about its risks to the liver, but the companies have never published those results, according to a "New York Times" article of Dec. 21. Partial results of the studies, alluded to in documents...
- Research articles 2008-01-15
- Merck Expresses Confidence in the Efficacy and Safety Profiles of ZETIA® (ezetimibe) and VYTORIN® (ezetimibe/simvastatin) as Effective Medicines for Managing Elevated Cholesterol
- ORLANDO, Fla. -- At the American Heart Association meeting today, Merck & Co., Inc. said it is confident in the safety and efficacy profiles of ZETIA® ezetimibe and VYTORIN®...
- Research articles 2009-11-15
- Study Raises New Questions About Cholesterol Drug Zetia
- A new study raises more questions about ezetimibe Zetia, a drug used by millions of Americans in tandem with statins to lower LDL, or "bad," cholesterol.The trial, known as ARBITER-6 HALTS, was stopped early in June after it was discovered that LDL-cholesterol-lowering Zetia was less effective than extended-release niacin Niaspan,...
- Research articles 2009-11-16
- African Americans Should Not Stop Taking Vytorin or Zetia Without Consulting Their Healthcare Providers
- To: MEDICAL EDITORS Contact: Keith Ferdinand, MD, +1-404-201-6632 ATLANTA, Jan. 24 /PRNewswire/ -- The recent release of the ENHANCE study of Vytorin and Zetia has drawn considerable media attention, but stopping cholesterol medications based on this study alone is not appropriate. The next step for any concerned patient with...
- Research articles 2008-01-24
- UPDATED: Why Zetia Researchers' Silence on Ending of Niaspan Trial Is Unfair to Merck
- Dr. Allen Taylor, an ARBITER-6 HALT trial investigator, should probably avoid talking to Merck investors for the next few weeks lest he get punched in the nose. It was Allen and his colleagues' unexplained announcement that they had stopped an Abbott Labs-funded comparison of Merck's Zetia with Abbott's Niaspan that...
- Blog posts 2009-07-10
- Leerink Bets Abbott's Niaspan Beat Merck/Schering's Zetia in Mystery Trial
- Wall Street analysts at Leerink Swann are betting that Abbott Labs' Niaspan did indeed beat Merck/Schering-Plough's Zetia in the ARBITER 6 imaging study. That was the study that was suddenly and mysteriously halted without explanation, causing a rash of speculation. by Jim Edwards
- Blog posts 2009-07-17
- Vytorin and Zetia continue to be prescribed despite hints of harms and no proof of benefit
- There is no proof that Zetia can do anything beyond lowering cholesterol--no evidence that it can reduce heart attacks or cardiovascular disease, which, of course, is the ultimate goal. Once again, this blockbuster drug sold alone or as a combination medicine has produced negative clinical trial results. This time it...
- Research articles 2008-10-01
- Amateur Hour at Merck: FDA Refuses to Look at Zetia-Lipitor Combo Pill
- Merck was sent back to the drawing board on its new Zetia-Lipitor combo drug when the FDA refused to accept its application. That's an unheard of gaffe for a Big Pharma firm. Merck slipped the news into its 10-Q filing with the SEC. by Jim Edwards
- Blog posts 2009-11-04
- Merck Statement on Zetia Mess Is a Masterpiece of Spin
- You might be forgiven for thinking that Abbott Labs ABT's Niaspan trounced Merck MRK's Zetia in a trial known as "Arbiter 6 HALTS," if you read the headlines today. You'd be wrong, as Merck explains in the following press release. by Jim Edwards
- Blog posts 2009-11-16
- << Previous
- page 1 of 1
- Next >>
